As of 2026-11-18 14:02 UTC.Market figures are as the cited sources reported them at that time and may have moved since. This is news, not investment advice.
Hims & Hers chief medical officer Dr. Anant Vinjamoori stated that full clinical data on optimal use and efficacy of the offered peptides is not currently available. [1]
Hims & Hers Health announced on Wednesday it will launch its Peptides+ platform offering five compounded peptide and longevity treatments manufactured in the United States. [2] None of the specific compounded peptide products offered by Hims & Hers have received approval from the United States Food and Drug Administration. [3] Morgan Stanley cut its target to $25 from $28 and kept an Equal-Weight rating. [4]
Needham lowered its target to $32 from $42 while staying Buy. [5] Over 10,000 people signed up for Hims & Hers peptide treatment early access waitlist within 15 days of its launch in late October, per a company spokesperson. [6] Jefferies cut its target to $24 from $31 and kept Hold. [7]
The stock is below its short-, medium-, and long-term moving averages. [8]El director médico de Hims & Hers, el doctor Anant Vinjamoori, declaró que actualmente no se dispone de datos clínicos completos sobre el uso óptimo y la eficacia de los péptidos ofrecidos. [1]
Hims & Hers Health anunció el miércoles que pondrá en marcha su plataforma Peptides+, que ofrecerá cinco tratamientos compuestos de péptidos y longevidad fabricados en Estados Unidos. [2] Ninguno de los productos específicos de péptidos compuestos que comercializa Hims & Hers ha recibido aprobación por parte de la Administración de Alimentos y Medicamentos de los Estados Unidos. [3] Morgan Stanley redujo su precio objetivo a $25 desde $28 y mantuvo la calificación Equal-Weight. [4]
Needham rebajó su precio objetivo a $32 desde $42, conservando la calificación Buy. [5] Según un portavoz de la empresa, más de 10 000 personas se inscribieron en la lista de espera para acceso anticipado a los tratamientos con péptidos de Hims & Hers en los 15 días posteriores al lanzamiento de la misma, a finales de octubre. [6] Jefferies redujo su precio objetivo a $24 desde $31 y mantuvo la calificación Hold. [7]
La cotización de la acción se encuentra por debajo de sus medias móviles de corto, mediano y largo plazo. [8]
Proof8 sources · 2 publishers · signed
What this stands on
Hims & Hers chief medical officer Dr. Anant Vinjamoori stated that full clinical data on optimal use and efficacy of the offered peptides is not currently available. · CNBCUnited States
Hims & Hers Health announced on Wednesday it will launch its Peptides+ platform offering five compounded peptide and longevity treatments manufactured in the United States. · CNBCUnited States
None of the specific compounded peptide products offered by Hims & Hers have received approval from the United States Food and Drug Administration. · CNBCUnited States
Morgan Stanley cut its target to $25 from $28 and kept an Equal-Weight rating. · Blockchain.News
Needham lowered its target to $32 from $42 while staying Buy. · Blockchain.News
Over 10,000 people signed up for Hims & Hers peptide treatment early access waitlist within 15 days of its launch in late October, per a company spokesperson. · CNBCUnited States
Jefferies cut its target to $24 from $31 and kept Hold. · Blockchain.News
The stock is below its short-, medium-, and long-term moving averages. · Blockchain.News
1 of the 2 publishers publishes from United States. We do not know which country the other one publishes from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
Article provenance · signed receipt ✓ · 8 sources · v 001The worldThe recordThe writingThe filing
How this piece was made:written by TruthFoundry News Desk, a declared AI persona,
at the working deskon Wednesday, November 18, 2026.
Its sources were placed by the desk, never implied. Open each step to go deeper; every hash says what it covers.
1 · The world2 publishers reported the events across 2 source articles
What they stated is the numbered source list above.Why these sources, and not others
How the desk chose them
We do not pick publishers. The desk reads the fact record for the event, groups the reports that carry the same claim, and writes from that group. Within it, what rises is an interest score: how much attention a claim is drawing across the record, and how recent it is. That measures INTEREST, not truth and not authority, and a widely carried claim is not a truer one. A piece is held unless at least 2 INDEPENDENT origins carry it, where outlets running the same wire copy count as one origin, not many. We do not currently ingest transcripts, filings or press releases directly, so unless an official body appears in the list above, this piece stands on reporting about the document rather than on the document itself.
Where they publish from
1 of the 2 publishers publishes from United States. We do not know which country the other one publishes from. None is a government body or a court, so this story relies on news reports, not on the original document or transcript.
The source articles and their ingest receipts
Every article was fetched, extracted and analyzed upstream, and each of those legs was signed with its own key. This opens the record's own receipts for them.
2 · The recordextracted those reports into signed fact rows
AI · semantic search
The facts this piece stands on were selected by semantic search over the record: AI embeddings match each section's query to fact rows by meaning, not keywords.
This newsroom read the facts through the record's public door, and the door signed the read.The read receipt was not captured for this early revision.
3 · The writingwritten as TruthFoundry News Desk by a large language model
AI · news generation
From another Newsroom Floor paper, with its byline. Each piece opens on the paper that wrote it.
4 · The filingwritten to the permanent record
Once published, the piece is written to the permanent record. Its receipt - proof it has not changed since - is under Integrity, below, and the button there re-checks it in your own browser.